PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
18.14
-0.11 (-0.60%)
Apr 16, 2026, 1:17 PM EDT - Market open
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
$114,125
Profits / Employee
$904,964
Market Cap
433.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Ginkgo Bioworks Holdings | 485 |
| Invivyd | 122 |
| Enanta Pharmaceuticals | 120 |
| Aura Biosciences | 113 |
| Century Therapeutics | 78 |
| Armata Pharmaceuticals | 60 |
| Altimmune | 57 |
PRTC News
- 3 days ago - PureTech Health: Notice of Results - Business Wire
- 14 days ago - PureTech Health (PRTC) Advances Deupirfenidone for Pulmonary Fibrosis Treatment - GuruFocus
- 14 days ago - PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine - Business Wire
- 21 days ago - PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - Business Wire
- 7 weeks ago - PureTech to Present at the Leerink Partners Global Healthcare Conference - Business Wire
- 2 months ago - PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 3 months ago - PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire